• Apollomics posted fiscal 2025 net loss of USD 10.9 million, narrowing from USD 53.9 million a year earlier.
• Revenue was USD 8.5 million, versus no revenue in fiscal 2024.
• Research and development expenses fell 77.5% to USD 5.53 million as the company narrowed its development focus.
• Cash and cash equivalents declined to USD 3.28 million at Dec. 31, 2025, from USD 9.77 million a year earlier.
• Management flagged substantial doubt about ability to continue as a going concern through April 30, 2027, despite expected receipt of a USD 2.3 million LaunXP receivable in Q2 2026 and a USD 2 million unsecured bridge loan from Chairman and CEO Hung-Wen (Howard) Chen on March 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apollomics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-177357), on April 24, 2026, and is solely responsible for the information contained therein.